Similarly, KDM4A was overexpressed in ESCC patients who did not respond to anti-PD1 therapy, and application of KDM4 inhibitor (KDM4-IN-4) followed by anti-PD1 therapy led to pronounced suppression of tumor growth in vivo [84]. The gene discussed is KDM4A; the disease is esophageal squamous cell carcinoma.